Skip to main content
Premium Trial:

Request an Annual Quote

Steven Ruben, Martin Latterich, John Varian


Steven Ruben has been appointed vice president for protein therapeutics at Celera Genomics. He will lead target discovery programs for therapeutic antibodies and oversee the company’s cell biology, protein chemistry, and mass spectrometry efforts. He joins Celera from Human Genome Sciences, where he was vice president for research.


Martin Latterich has left his post as director of proteomics at Illumina, to become an associate professor at the Faculty of Medicine of McGill University in Montreal in July. Meanwhile, he is an adjunct assistant professor at the Salk Institute for Biological Studies in La Jolla, Calif. Latterich holds a PhD in molecular cell biology from the University of Durham, UK.


John Varian will become CFO of Deltagen as soon as the company closes a preferred stock private placement it announced in early April. Until then, he will serve as interim CFO. Varian was CFO of Genset from 2000 to 2002. From 1998 to 2000, he was senior vice president for finance and administration at Elan Pharmaceuticals, and before that, CFO at Neurex, which Elan acquired in 1998. He was also previously CFO of Anergen. Varian holds a BBA from Western Michigan University.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.